Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ian Nessler"'
Autor:
Radhika Narain, Ian Nessler, Paul L. Richardson, Jamie E. Erickson, Yuzhen Wang, Jacqueline Ferri, Heather L. Knight, Shaughn H. Bryant, Lucy A. Phillips, Liang Zhang, Soumya Mitra
Publikováno v:
npj Imaging, Vol 2, Iss 1, Pp 1-11 (2024)
Abstract In this work, the impact of physicochemical modifications on pharmacokinetics and in vivo targeting of a small molecule fibroblast activation protein inhibitor (FAPI) imaging ligand in a murine model of rheumatoid arthritis was evaluated. Wh
Externí odkaz:
https://doaj.org/article/821384118fe54bc18bf98f999d4cbfe8
Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
Autor:
Eshita Khera, Cornelius Cilliers, Michael D. Smith, Michelle L. Ganno, Katharine C. Lai, Thomas A. Keating, Anna Kopp, Ian Nessler, Adnan O. Abu-Yousif, Greg M. Thurber
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 2, Pp 210-221 (2021)
With the recent approval of 3 new antibody drug conjugates (ADCs) for solid tumors, this class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant investment, there are still fundamental issues that are incompletely
Externí odkaz:
https://doaj.org/article/a1d49a829b1446a5941d3e371fc652ef
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Preclinical in vivo studies form the cornerstone of drug development and translation, bridging in vitro experiments with first-in-human trials. However, despite the utility of animal models, translation from the bench to bedside remains difficult, pa
Externí odkaz:
https://doaj.org/article/f28851479b384140a9613e2d68f6e4dc
Publikováno v:
Pharmaceutics, Vol 12, Iss 2, p 132 (2020)
Many tools for studying the pharmacokinetics of biologics lack single-cell resolution to quantify the heterogeneous tissue distribution and subsequent therapeutic degradation in vivo. This protocol describes a dual-labeling technique using two near-i
Externí odkaz:
https://doaj.org/article/bc0d926012c140dd87fb81b1155fe768
Autor:
Greg M. Thurber, Normann Goodwin, Lorraine Thompson, James Legg, Thomas Sandal, Adnan O. Abu-Yousif, Thomas A. Keating, Qifeng Qiu, Anna Kopp, Steven Vance, Eshita Khera, Ian Nessler
Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by concentrating drugs at the site-of-action, a method embodied by the seven current FDA-approved antibody–drug conjugates (ADC). However, a variety of pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bb7ab2805dd13cdbb4ee95f79492b5
https://doi.org/10.1158/0008-5472.c.6511984.v1
https://doi.org/10.1158/0008-5472.c.6511984.v1
The supplementary data file includes additional immunofluorescence microscopy images showing the tumor distribution of T-DM1-680 alone, T-DM1-680 with unlabeled trastuzumab, and a higher dose of T-DM1-680. Supplemental in vitro assays include: single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a961aaa889f1fd84340d16d487d55bf4
https://doi.org/10.1158/0008-5472.22417799.v1
https://doi.org/10.1158/0008-5472.22417799.v1
Current antibody–drug conjugates (ADC) have made advances in engineering the antibody, linker, conjugation site, small-molecule payload, and drug-to-antibody ratio (DAR). However, the relationship between heterogeneous intratumoral distribution and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7642f38d7ec17a4d5c3166c3eab2a24c
https://doi.org/10.1158/0008-5472.c.6509948
https://doi.org/10.1158/0008-5472.c.6509948
Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
Autor:
Katharine C. Lai, Michael D. Smith, Ian Nessler, Anna Kopp, Cornelius Cilliers, Thomas A. Keating, Adnan O. Abu-Yousif, Greg M. Thurber, Michelle L. Ganno, Eshita Khera
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 2, Pp 210-221 (2021)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 2, Pp 210-221 (2021)
With the recent approval of 3 new antibody drug conjugates (ADCs) for solid tumors, this class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant investment, there are still fundamental issues that are incompletely
Autor:
Thomas Sandal, Ian Nessler, Steven Vance, Thomas A. Keating, Anna Kopp, Lorraine Thompson, Eshita Khera, Adnan O. Abu-Yousif, Qifeng Qiu, Greg M. Thurber, Normann Goodwin, James Legg
Publikováno v:
Cancer Research. 80:1268-1278
Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by concentrating drugs at the site-of-action, a method embodied by the seven current FDA-approved antibody–drug conjugates (ADC). However, a variety of pharmacokine
Publikováno v:
Trends Pharmacol Sci
Although the recent FDA approval of six new antibody–drug conjugates (ADCs) is promising, attrition of ADCs during clinical development remains high. The inherent complexity of ADCs is a double-edged sword that provides opportunities for perfecting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4084e6544db80b8275c2536dfea5d970
https://europepmc.org/articles/PMC8519343/
https://europepmc.org/articles/PMC8519343/